NASDAQ$GEHC
GE HealthCare Technologies Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
GE HealthCare reported Q3 2025 total revenues of $5.14B with net income of $446M and diluted EPS of $0.98.
Total revenues were $5.14 billion for the quarter ended September 30, 2025, with net income of $446 million and diluted EPS of $0.98. Imaging, ultrasound, and patient care solutions benefited from procedure volumes and product launches while the company managed tariffs and supply-chain costs.
- Q3 total revenues $5.14B; net income $446M; diluted EPS $0.98.
- Orders and backlog support multi-quarter revenue visibility.
- Tariffs and FX remain margin and guidance variables.
- R&D and AI-enabled product roadmaps target share gains in medtech.
Headline financials
Revenue & EPS history
GE HealthCare · Revenue · Quarterly
$5.14B
Revenue by segment
GE HealthCare · $4.01B total across 4 segments · Q3 2023
- Imaging$2.64B+4.7%65.8%
- Patient Care$764M+9.0%19.1%
- Pharma Diagnostics$589M+12.8%14.7%
- Other$19M+35.7%0.5%
Forward guidance
The filing discusses GE HealthCare's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- GE HealthCare cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q3 2025
-0.2%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.3%
Avg return
30 days after
50%
8 / 16 earnings
Positive
+11.5%
Q4 2021
Best reaction
-12.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.9% | -10.9% | -8.9% | |
| Q4 2025 | +6.4% | +0.4% | -5.7% | |
| Q3 2025 | -2.7% | -6.2% | +0.7% | |
| Q1 2025 | +3.3% | +1.9% | +3.6% | |
| Q4 2024 | +8.8% | +7.9% | -4.6% | |
| Q3 2024 | +2.4% | +2.0% | -2.4% | |
| Q2 2024 | +0.9% | -1.4% | +2.6% | |
| Q1 2024 | -12.0% | -10.6% | -11.7% | |
| Q4 2021 | +11.5% | +10.8% | +26.2% | |
| Q3 2023 | +8.1% | +13.3% | +8.4% | |
| Q3 2022 | +8.1% | +13.3% | +8.4% | |
| Q2 2023 | -4.0% | -3.4% | -15.1% | |
| Q1 2023 | -8.7% | -7.3% | -9.0% | |
| Q1 2022 | -8.7% | -7.3% | -9.0% | |
| Q2 2022 | -2.3% | +0.8% | +4.4% | |
| Q4 2022 | -0.8% | +0.7% | +7.4% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro